Regulation of the MDM2-P53 pathway and tumor growth by PICT1 via nucleolar RPL11

Nature Medicine

Volumn 17, Issue 8, 2011, Pages 944-951

  Sasaki, Masato ^a   Kawahara, Kohichi ^b   Nishio, Miki ^b   Mimori, Koshi ^b   Kogo, Ryunosuke ^b   Hamada, Koichi ^b   Itoh, Bunsho ^b   Wang, Jia ^b   Komatsu, Yukako ^b   Yang, Yong Ryoul ^b   Hikasa, Hiroki ^b   Horie, Yasuo ^a   Yamashita, Takayuki ^c   Kamijo, Takehiko ^d   Zhang, Yanping ^e   Zhu, Yan ^f   Prives, Carol ^f   Nakano, Toru ^g   Mak, Tak Wah ^h   Sasaki, Takehiko ^a   Maehama, Tomohiko ⁱ   Mori, Masaki ^b,g   Suzuki, Akira ^a,b   more..

^a AKITA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c GUNMA UNIVERSITY   (Japan)

^d CHIBA CANCER CENTER   (Japan)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f Och Spine at New York Presbyterian Hospitals   (United States)

^g OSAKA UNIVERSITY   (Japan)

^h UNIVERSITY HEALTH NETWORK   (Canada)

ⁱ NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEOLIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MDM2; PROTEIN P53; PROTEIN PICT1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL SURVIVAL; DNA DAMAGE; EMBRYO DEVELOPMENT; EMBRYONIC STEM CELL; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; NUCLEOLUS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR GROWTH; UBIQUITINATION;

ANIMALS; BLOTTING, NORTHERN; CELL NUCLEOLUS; CELL PROLIFERATION; EMBRYONIC STEM CELLS; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; IN SITU NICK-END LABELING; INDOLES; MICE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MDM2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBOSOMAL PROTEINS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

MUS;

EID: 79961145353     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2392     Document Type: Article

References (53)

1. Toledo, F. & Wahl, G.M. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat. Rev. Cancer 6, 909-923 (2006). (Pubitemid 44862676)
2. Kubbutat, M.H., Jones, S.N. & Vousden, K.H. Regulation of p53 stability by Mdm2. Nature 387, 299-303 (1997). (Pubitemid 27220767)
3. Haupt, Y., Maya, R., Kazaz, A. & Oren, M. Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299 (1997). (Pubitemid 27220766)
4. Kruse, J.P. & Gu, W. Modes of p53 regulation. Cell 137, 609-622 (2009).
5. Zhang, Y., Xiong, Y. & Yarbrough, W.G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92, 725-734 (1998). (Pubitemid 28155312)
6. Pomerantz, J. et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2′s inhibition of p53. Cell 92, 713-723 (1998). (Pubitemid 28155311)
7. Lindström, M.S., Deisenroth, C. & Zhang, Y. Putting a finger on growth surveillance: insight into MDM2 zinc finger-ribosomal protein interactions. Cell Cycle 6, 434-437 (2007). (Pubitemid 46393446)
8. Lohrum, M.A., Ludwig, R.L., Kubbutat, M.H., Hanlon, M. & Vousden, K.H. Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 3, 577-587 (2003). (Pubitemid 36808652)
9. Zhang, Y. et al. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol. Cell. Biol. 23, 8902-8912 (2003). (Pubitemid 37433388)
10. Dai, M.S. & Lu, H. Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J. Biol. Chem. 279, 44475-44482 (2004). (Pubitemid 39430853)
11. Jin, A., Itahana, K., O'Keefe, K. & Zhang, Y. Inhibition of HDM2 and activation of p53 by ribosomal protein L23. Mol. Cell. Biol. 24, 7669-7680 (2004). (Pubitemid 39121492)
12. Zhu, Y. et al. Ribosomal protein S7 is both a regulator and a substrate of MDM2. Mol. Cell 35, 316-326 (2009).
13. Fumagalli, S. et al. Absence of nucleolar disruption after impairment of 40S ribosome biogenesis reveals an rpL11-translation-dependent mechanism of p53 induction. Nat. Cell Biol. 11, 501-508 (2009).
14. Zhang, Y. & Lu, H. Signaling to p53: ribosomal proteins find their way. Cancer Cell 16, 369-377 (2009).
15. Warner, J.R. & McIntosh, K.B. How common are extraribosomal functions of ribosomal proteins? Mol. Cell 34, 3-11 (2009).
16. Chen, D. et al. Ribosomal protein S7 as a novel modulator of p53-MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function. Oncogene 26, 5029-5037 (2007). (Pubitemid 47206956)
17. Bhat, K.P., Itahana, K., Jin, A. & Zhang, Y. Essential role of ribosomal protein L11 in mediating growth inhibition-induced p53 activation. EMBO J. 23, 2402-2412 (2004). (Pubitemid 38954847)
18. Rubbi, C.P. & Milner, J. Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. EMBO J. 22, 6068-6077 (2003). (Pubitemid 37463250)
19. Sun, X.X., Dai, M.S. & Lu, H. Mycophenolic acid activation of p53 requires ribosomal proteins L5 and L11. J. Biol. Chem. 283, 12387-12392 (2008).
20. Sulic, S. et al. Inactivation of S6 ribosomal protein gene in T lymphocytes activates a p53-dependent checkpoint response. Genes Dev. 19, 3070-3082 (2005). (Pubitemid 41798121)
21. Takagi, M., Absalon, M.J., McLure, K.G. & Kastan, M.B. Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell 123, 49-63 (2005). (Pubitemid 41414528)
22. Yadavilli, S. et al. Ribosomal protein S3: a multi-functional protein that interacts with both p53 and MDM2 through its KH domain. DNA Repair (Amst.) 8, 1215-1224 (2009).
23. Smith, J.S. et al. A transcript map of the chromosome 19q-arm glioma tumor suppressor region. Genomics 64, 44-50 (2000). (Pubitemid 30165073)
24. Kim, Y.J. et al. Suppression of putative tumour suppressor gene GLTSCR2 expression in human glioblastomas. J. Pathol. 216, 218-224 (2008).
25. Nakagawa, Y. et al. Chromosomal imbalances in malignant peripheral nerve sheath tumor detected by metaphase and microarray comparative genomic hybridization. Oncol. Rep. 15, 297-303 (2006).
26. Merritt, M.A. et al. Expression profiling identifies genes involved in neoplastic transformation of serous ovarian cancer. BMC Cancer 9, 378 (2009).
27. Yim, J.H. et al. The putative tumor suppressor gene GLTSCR2 induces PTEN-modulated cell death. Cell Death Differ. 14, 1872-1879 (2007).
28. Okahara, F., Ikawa, H., Kanaho, Y. & Maehama, T. Regulation of PTEN phosphorylation and stability by a tumor suppressor candidate protein. J. Biol. Chem. 279, 45300-45303 (2004). (Pubitemid 39491510)
29. Okahara, F. et al. Critical role of PICT-1, a tumor suppressor candidate, in phosphatidylinositol 3,4,5-trisphosphate signals and tumorigenic transformation. Mol. Biol. Cell 17, 4888-4895 (2006). (Pubitemid 44665757)
30. Cairncross, J.G. et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl. Cancer Inst. 90, 1473-1479 (1998). (Pubitemid 28482012)
31. Smith, J.S. et al. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 18, 4144-4152 (1999). (Pubitemid 29363922)
32. Mariani, L. et al. Loss of heterozygosity 1p36 and 19q13 is a prognostic factor for overall survival in patients with diffuse WHO grade 2 gliomas treated without chemotherapy. J. Clin. Oncol. 24, 4758-4763 (2006). (Pubitemid 46630940)
33. von Deimling, A. et al. Loci associated with malignant progression in astrocytomas: a candidate on chromosome 19q. Cancer Res. 54, 1397-1401 (1994). (Pubitemid 24106394)
34. Smith, J.S. et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J. Clin. Oncol. 18, 636-645 (2000). (Pubitemid 30078545)
35. Miyazaki, M. et al. Thymocyte proliferation induced by pre-T cell receptor signaling is maintained through polycomb gene product Bmi-1-mediated Cdkn2a repression. Immunity 28, 231-245 (2008). (Pubitemid 351215231)
36. Kamijo, T. et al. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. USA 95, 8292-8297 (1998). (Pubitemid 28326106)
37. Solozobova, V. & Blattner, C. Regulation of p53 in embryonic stem cells. Exp. Cell Res. 316, 2434-2446 (2010).
38. Zhao, X. et al. The HECT-domain ubiquitin ligase Huwe1 controls neural differentiation and proliferation by destabilizing the N-Myc oncoprotein. Nat. Cell Biol. 10, 643-653 (2008). (Pubitemid 351772930)
39. Barak, Y., Juven, T., Haffner, R. & Oren, M. mdm2 expression is induced by wild type p53 activity. EMBO J. 12, 461-468 (1993). (Pubitemid 23073692)
40. Kurki, S. et al. Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer Cell 5, 465-475 (2004). (Pubitemid 38610248)
41. Dai, M.S., Sun, X.X. & Lu, H. Aberrant expression of nucleostemin activates p53 and induces cell cycle arrest via inhibition of MDM2. Mol. Cell. Biol. 28, 4365-4376 (2008). (Pubitemid 351904958)
42. Saxena, A., Rorie, C.J., Dimitrova, D., Daniely, Y. & Borowiec, J.A. Nucleolin inhibits Hdm2 by multiple pathways leading to p53 stabilization. Oncogene 25, 7274-7288 (2006). (Pubitemid 44809093)
43. Russo, A. et al. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J. Clin. Oncol. 23, 7518-7528 (2005). (Pubitemid 46291815)
44. Egashira, A. et al. p53 gene mutations in esophageal squamous cell carcinoma and their relevance to etiology and pathogenesis: results in Japan and comparisons with other countries. Cancer Sci. 98, 1152-1156 (2007). (Pubitemid 46993534)
45. Kim, J.Y., Kim, H.S., Lee, S. & Park, J.H. The expression of GLTSCR2, a candidate tumor suppressor, is reduced in seborrheic keratosis compared to normal skin. Pathol. Res. Pract. 206, 295-299 (2010).
46. Okamoto, Y. et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol. 108, 49-56 (2004). (Pubitemid 38961073)
47. Andersen, J.S. et al. Nucleolar proteome dynamics. Nature 433, 77-83 (2005). (Pubitemid 40101146)
48. Era, T. & Witte, O.N. Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate. Proc. Natl. Acad. Sci. USA 97, 1737-1742 (2000). (Pubitemid 30118512)
49. Kitajima, K., Masuhara, M., Era, T., Enver, T. & Nakano, T. GATA-2 and GATA-2/ER display opposing activities in the development and differentiation of blood progenitors. EMBO J. 21, 3060-3069 (2002). (Pubitemid 34670390)
50. Okahara, F. et al. Production of research-grade antibody by in vivo electroporation of DNA-encoding target protein. Anal. Biochem. 336, 138-140 (2005). (Pubitemid 39593511)
51. Inoue-Narita, T. et al. Pten deficiency in melanocytes results in resistance to hair graying and susceptibility to carcinogen-induced melanomagenesis. Cancer Res. 68, 5760-5768 (2008).
52. Furukawa, M., Zhang, Y., McCarville, J., Ohta, T. & Xiong, Y. The CUL1 C-terminal sequence and ROC1 are required for efficient nuclear accumulation, NEDD8 modification, and ubiquitin ligase activity of CUL1. Mol. Cell. Biol. 20, 8185-8197 (2000).
53. Feng, L., Lin, T., Uranishi, H., Gu, W. & Xu, Y. Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol. Cell. Biol. 25, 5389-5395 (2005). (Pubitemid 40853576)